Pharmaceutical advertising versus research spending: Are profits more important than patients?

American Heart Journal

Volumn 146, Issue 4, 2003, Pages 563-564

  Mukherjee, Debabrata ^a   Topol, Eric J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIOBESITY AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; CELECOXIB; FEXOFENADINE; FLUTICASONE PROPIONATE; HYPOCHOLESTEROLEMIC AGENT; LORATADINE; PAROXETINE; PRISOLEC; ROFECOXIB; SIBUTRAMINE; SILDENAFIL; SIMVASTATIN; STEROID;

ADVERTIZING; BUDGET; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; EDITORIAL; HIGH RISK POPULATION; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PROFIT; PUBLICATION;

EID: 0142088822     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00399-5     Document Type: Editorial

References (15)

1. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002;346:498-505.
2. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989;28:577-82.
3. Ingelfinger FJ. Advertising: informative but not educational. N Engl J Med 1972;286:1318-9.
4. Leacock S. The garden of folly. New York: Dodd Mead; 1924.
5. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion? N Engl J Med 2002;346:524-6.
6. Merck & Co. 2001 Annual Report; 2002. http://www.anrpt2001. com/01arfinancials.pdf.
7. Pharmacia. Pharmacia 2001 annual report. PeaPack, NJ; 2002. http://media.corporate-ir.net/media_files/NYS/PHA/reports/ ar2001.pdf.
8. Ray W, Stein C, Daugherty J, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071.
9. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
10. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
11. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001;104:820-5.
12. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
13. Congressional Record. Proceedings and debates of the 107th congress, second session. In: United States Senate. Washington, DC; May 9, 2002. http://stabenow.senate.gov/rx/050902cr_drugs. htm.
14. Frisch E. Coxibs supplement: has CCJM sold out? Cleve Clin J Med 2002;69:568.
15. NIH. Prescription Drugs and Mass Media Advertising, 2000: A research report by The National Institute for Health Care Management Research and Educational Foundation. Washington, DC: National Institute of Health; 2001. http://www.nihcm.org/ DTCbrief2001.pdf.